India to Australia: Escitalopram Export Trade Route

The India to Australia Escitalopram corridor is one of India's established pharmaceutical export routes, with 198 shipments documented worth a combined $8.3M USD. The route is dominated by CIPLA LIMITED, which alone accounts for roughly 39% of all export value, reflecting the consolidated nature of India's escitalopram manufacturing sector.

Across 5 active suppliers, the average shipment value stands at $41.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with escitalopram's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 17.4%, placing it at rank #19 among India's top escitalopram export destinations globally.

On the import side, key buyers of Indian escitalopram in Australia include NA, SANDOZ PTY LTD, , SANDOZ PTY LTD and 15 others. NA is the single largest importer with 42 shipments valued at $2.4M USD.

India's escitalopram exports to Australia are driven primarily by a handful of large-scale manufacturers. CIPLA LIMITED with 105 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 5 active exporters signals a competitive but concentrated market — buyers in Australia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA LIMITED, IPCA LABORATORIES LIMITED, CIPLA LIMITED — together account for 95% of total trade value on this route. The average shipment value of $41.9K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as escitalopram sandoz (as oxalate) 10 mg t and apo-escitalopram 10mg tabletsescitalopr, suggesting that buyers in Australia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, NA is the largest importer with 42 shipments worth $2.4M USD — representing 29% of all escitalopram imports from India on this route. A total of 18 buyers are active on this corridor.